BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 34816022)

  • 1. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
    le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.
    Marotte D; Gal J; Schiappa R; Gautier M; Boulahssass R; Chand-Fouche ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jul; 35():104-109. PubMed ID: 35692263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
    Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
    Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis.
    Martz N; Bodokh Y; Gautier M; Thamphya B; Schiappa R; Lam Cham Kee D; Chevallier D; Hannoun A; Chand ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2021 Mar; 27():89-95. PubMed ID: 33537466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
    Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
    Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of single insertion accelerated MR-image guided brachytherapy following chemo-radiation in locally advanced cervix cancer: modifying our EMBRACE during the COVID pandemic.
    Stevens MJ; Ko F; Martland J; Brown R; Bell L; Atyeo J; Yim J
    Radiat Oncol; 2023 Mar; 18(1):54. PubMed ID: 36941643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial.
    Hannoun-Levi JM; Chand-Fouche ME; Pace-Loscos T; Gautier M; Gal J; Schiappa R; Pujol N
    Clin Transl Radiat Oncol; 2022 Nov; 37():64-70. PubMed ID: 36093342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed Tomography-Planned High-Dose-Rate Brachytherapy for Treating Uterine Cervical Cancer.
    Zolciak-Siwinska A; Gruszczynska E; Bijok M; Jonska-Gmyrek J; Dabkowski M; Staniaszek J; Michalski W; Kowalczyk A; Milanowska K
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):87-92. PubMed ID: 27375169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proof of principle: Applicator-guided stereotactic IMRT boost in combination with 3D MRI-based brachytherapy in locally advanced cervical cancer.
    Assenholt MS; Vestergaard A; Kallehauge JF; Mohamed S; Nielsen SK; Petersen JB; Fokdal L; Lindegaard JC; Tanderup K
    Brachytherapy; 2014; 13(4):361-8. PubMed ID: 24656732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of MRI-Guided Adaptive Brachytherapy for Each Fraction in Locally Advanced Cervical Cancer: A Single Institution Experience.
    Chi Y; Pan Y; Zhang N; Han D; Guo X; Mao Z; Cheng G
    Front Oncol; 2022; 12():841980. PubMed ID: 35372065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.
    Ribeiro I; Janssen H; De Brabandere M; Nulens A; De Bal D; Vergote I; Van Limbergen E
    Radiother Oncol; 2016 Sep; 120(3):447-454. PubMed ID: 27157510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour.
    Lu S; Wang S; Kim RY; Zhang J; Wang X; Wang W; Zhu G; Zhou J; Tan Y; Tan M; Li M; Yin G; Li J; Feng M; Lang J
    BJOG; 2023 Jan; 130(2):231-237. PubMed ID: 36330947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy.
    Lazzari R; Riva G; Augugliaro M; Vavassori A; Dicuonzo S; Cattani F; Comi S; Colombo N; Jereczek-Fossa BA
    Int J Gynecol Cancer; 2020 May; 30(5):607-612. PubMed ID: 32188626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
    Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
    Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.
    Pötter R; Tanderup K; Schmid MP; Jürgenliemk-Schulz I; Haie-Meder C; Fokdal LU; Sturdza AE; Hoskin P; Mahantshetty U; Segedin B; Bruheim K; Huang F; Rai B; Cooper R; van der Steen-Banasik E; Van Limbergen E; Pieters BR; Tan LT; Nout RA; De Leeuw AAC; Ristl R; Petric P; Nesvacil N; Kirchheiner K; Kirisits C; Lindegaard JC;
    Lancet Oncol; 2021 Apr; 22(4):538-547. PubMed ID: 33794207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer.
    Dincer N; Ugurluer G; Mustafayev TZ; Serkizyan A; Aydin G; Güngör G; Yapici B; Atalar B; Özyar E
    Brachytherapy; 2024; 23(1):18-24. PubMed ID: 38000958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
    Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
    Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal.
    Bertin E; Benezery K; Kee DLC; François E; Evesque L; Gautier M; Gerard JP; Hannoun-Levi JM; Falk AT
    J Contemp Brachytherapy; 2018 Dec; 10(6):522-531. PubMed ID: 30662475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes and Toxicity of CT-guided High Dose-rate Brachytherapy in Women With Locally-advanced Cervical Cancer.
    DE Sanctis V; Facondo G; Vullo G; Anzellini D; Sanguineti G; Nardangeli A; Marmiroli L; Tortoreto F; Gentile P; Annessi I; Donato V; Chiostrini C; Tombolini V; DE Felice F; Valeriani M; Osti MF
    Cancer Diagn Progn; 2023; 3(2):194-200. PubMed ID: 36875316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.